KalVista Pharmaceuticals (KALV) Cash & Current Investments (2016 - 2024)
Historic Cash & Current Investments for KalVista Pharmaceuticals (KALV) over the last 10 years, with Q4 2024 value amounting to $268.3 million.
- KalVista Pharmaceuticals' Cash & Current Investments changed N/A to $268.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $268.3 million, marking a year-over-year change of. This contributed to the annual value of $210.4 million for FY2024, which is N/A changed from last year.
- KalVista Pharmaceuticals' Cash & Current Investments amounted to $268.3 million in Q4 2024.
- KalVista Pharmaceuticals' Cash & Current Investments' 5-year high stood at $268.3 million during Q4 2024, with a 5-year trough of $50.3 million in Q1 2021.
- Over the past 4 years, KalVista Pharmaceuticals' median Cash & Current Investments value was $91.9 million (recorded in 2020), while the average stood at $117.5 million.
- Its Cash & Current Investments has fluctuated over the past 5 years, first plummeted by 4021.68% in 2020, then skyrocketed by 4138.91% in 2024.
- Over the past 4 years, KalVista Pharmaceuticals' Cash & Current Investments (Quarter) stood at $55.9 million in 2020, then decreased by 9.96% to $50.3 million in 2021, then soared by 105.07% to $103.2 million in 2023, then skyrocketed by 160.09% to $268.3 million in 2024.
- Its last three reported values are $268.3 million in Q4 2024, $135.8 million for Q4 2024, and $174.3 million during Q3 2024.